Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Esophageal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 44Fluorouracil 16Cisplatin 15Oxaliplatin 13Capecitabine 11Paclitaxel 10lenvatinib 8Leucovorin 8Irinotecan 6Docetaxel 6trifluridine tipiracil drug combination 3regorafenib 3Saline Solution 3Levoleucovorin 3Gemcitabine 3Bevacizumab 3patritumab deruxtecan 2Trastuzumab 2S 1 (combination) 2Radiotherapy 2Cetuximab 2Carboplatin 2zanidatamab 1vicriviroc 1tremelimumab 1tislelizumab 1tipiracil 1spartalizumab 1sinoporphyrin sodium 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × patritumab deruxtecan × Gastrointestinal × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡